
March 2, 2011 – FDA Drug Safety Communication issued over increased risk of low magnesium levels (hypomagnesemia) associated with proton pump inhibitor use.
March 2, 2011 – FDA Drug Safety Communication issued over increased risk of low magnesium levels (hypomagnesemia) associated with proton pump inhibitor use.